Condition: Gram-negative Bacteraemia · Sponsor: Tan Tock Seng Hospital
Current management of uncomplicated Gram-negative bacteraemia entails prolong intravenous (IV) antibiotic therapy with limited evidence to guide oral conversion. This trial aim to evaluate the clinical efficacy and economic impact of early switch to oral antibiotics (within 72 hours from index blood culture collection) versus continuing standard of care IV therapy (for at least another 24 hours post-randomisation) for clinically stable / non-critically ill inpatients with uncomplicated Gram-negative bacteraemia.
This description comes directly from the study's public registry record.
David Lye, MBBS · (65) 63577457 · david.lye@nhghealth.com.sg
I. Russel Lee, PhD · (65) 65115060 · lee.mc.ivor.russel@nhghealth.com.sg
Always discuss trial participation with your own doctor first.
| Tan Tock Seng Hospital | Singapore, Singapore, Singapore | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05199324